through the activation of SIGMAR1
Our proprietary SIGMACEPTOR™ Discovery Platform produces small molecule therapeutic candidates, like ANAVEX®2-73, with novel modes of action.
SIGMAR1 prevents toxic RNA from translating into proteins
ANAVEX®2-73 bound to SIGMAR1
SIGMAR1 protects healthy gene expression through Chromatin Remodeling
When activated by SIGMAR1 agonists, like ANAVEX®2-73, SIGMAR1 reduces cellular stress before and after RNA gene transcription. Studies confirm the predictive biomarker of response established through SIGMAR1 mRNA expression.
Because of its role in maintaining neuronal homeostasis, sigma receptors show significant promise as viable targets for therapeutic molecules in an effort to address a variety of CNS conditions.